Foresite Capital Management IV, LLC Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0001704132

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 6 positions · Total reported value $290.15M · Top-10 concentration 100.0% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 44.4% · 1 new · 0 cut · 3 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +20.5% · vs SPY +5.6% · Prev Value $237.08M — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, Foresite Capital Management IV, LLC disclosed 6 equity positions with a combined reported value of $290.15M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were PHVS ($165.24M), CYTK ($60.88M), EIKN ($25.37M). By sector, the heaviest allocations are Health Care 98.1%, Other 1.9%. Versus the prior quarter, allocation shifted toward Other (+1.9pp) and away from Health Care (-1.9pp).

Versus the prior quarter, Foresite Capital Management IV, LLC opened 1 new positions, trimmed 0 and fully exited 3, a turnover rate of 44.4% of positions. The portfolio's overlap with the prior quarter was 56% of names.

The largest new positions opened in Q2 2026 were CRNX ($5.61M).

Of the 3 positions fully exited versus the prior quarter, the largest were LYEL ($16.06M), ALEC ($8.36M), MAZE ($4.68M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • CRNX CRINETICS PHARMACEUTICALS IN · $5.61M

Fully Exited (vs previous quarter)

  • LYEL LYELL IMMUNOPHARMA INC · prev qtr: $16.06M
  • ALEC ALECTOR INC · prev qtr: $8.36M
  • MAZE MAZE THERAPEUTICS INC · prev qtr: $4.68M

Insider Transactions (Form 4)

Latest Foresite Capital Management IV, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Foresite Capital Management IV, LLC files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 6 positions worth $290.15M in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 6 positions · $290.15M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: PHVS (PHARVARIS N V) at 57.0%
  • Average position size: $48.36M

Sector Tilt

  • Health Care 98.1%
  • (classified holdings cover 98% of value)

Quarterly Activity

  • Q2 2026: 1 new, 2 added, 3 exited
  • 3 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund seems to maintain a cautious yet opportunistic stance. It continues to hold onto existing positions with slight adjustments, indicating a preference for stability amidst potential opportunities. 2. Key Moves: - Added: Relay Therapeutics (RLAY) and Crinetics Pharmaceuticals (CRNX). RLAY, a biotechnology company, saw a 25% increase in shares held, reflecting a significant addition to the portfolio. CRNX, another biotechnology company, was added entirely to the portfolio. - Increased: Cytokine Therapeutics (CYTK) saw a 42% increase in shares, signifying a substantial addition to the fund's holdings. - Unchanged: Pharvaris N.V. (PHVS), Eikon Therapeutics Inc. (EIKN), and Xenon Pharmaceuticals Inc. (XENE) remained unchanged from the previous quarter. - Reduced: No positions were reduced significantly. 3. Portfolio Structure: - Passive/Active: The rebalancing appears more active, with a focus on adding new positions and increasing the stake in existing ones. - Sector Bias: The portfolio has a strong bias towards the healthcare sector, particularly biotechnology and pharmaceuticals. - Risk Appetite: The risk appetite is moderate to high, given the significant additions to positions in the healthcare sector, which is often considered higher risk due to its volatility. 4. Per-Holding One-Liner: - PHVS: Pharvaris N.V. - Developing treatments for rare blood disorders. (verified) - CYTK: Cytokine Therapeutics Inc. - Focused on the development of cytokine therapies for immune disorders. (verified) - EIKN: Eikon Therapeutics Inc. - Engaged in the development of treatments for neurological diseases. (verified) - RLAY: Relay Therapeutics Inc. - Specializes in small molecule drugs for cancer and metabolic diseases. (verified) - XENE: Xenon Pharmaceuticals Inc. - Develops novel drugs for neurological and psychiatric conditions. (verified) - CRNX: Crinetics Pharmaceuticals Inc. - Focused on developing drugs for endocrine and metabolic diseases. (unverified) 5. One-Sentence Style Summary: The fund maintained its focus on healthcare, particularly biotechnology, with strategic additions and increases in existing positions, signaling a commitment to the sector's potential growth.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 98.1%
Other 1.9%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 4.78M $165.24M 56.95%
56.95%
Hold
2 714.70K $60.88M 20.98%
20.98%
Add
3 1.94M $25.37M 8.74%
8.74%
Hold
4 1.25M $23.39M 8.06%
8.06%
Add
5 160.00K $9.66M 3.33%
3.33%
Hold
6 150.00K $5.61M 1.94%
1.94%
New

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 62% R 83% F1 71% (modelled on 2026-Q1; 5/10 hit)

Historical Backtest (10 quarters)

Avg precision 91% · recall 88% · F1 89% · avg rank error 1.7 · Top-10 turnover 11%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 100% 100% 100% PHVS · KURA · KNTE · SNDX · LYEL PHVS · KURA · KNTE · SNDX · LYEL
2024-Q2 80% 100% 89% PHVS · KURA · KNTE · SNDX · LYEL PHVS · KURA · SNDX · LYEL
2024-Q3 100% 80% 89% PHVS · KURA · SNDX · LYEL PHVS · KURA · SNDX · LYEL · RLAY
2024-Q4 80% 100% 89% PHVS · KURA · SNDX · LYEL · RLAY PHVS · KURA · LYEL · RLAY
2025-Q1 100% 80% 89% PHVS · KURA · LYEL · RLAY PHVS · MAZE · LYEL · KURA · RLAY
2025-Q2 100% 83% 91% PHVS · MAZE · LYEL · KURA · RLAY PHVS · MAZE · LYEL · XENE · KURA · RLAY
2025-Q3 83% 83% 83% PHVS · MAZE · LYEL · XENE · KURA · RLAY PHVS · CYTK · MAZE · LYEL · XENE · RLAY
2025-Q4 100% 86% 92% PHVS · CYTK · MAZE · LYEL · XENE · RLAY PHVS · CYTK · LYEL · MAZE · RLAY · XENE · ALEC
2026-Q1 100% 88% 93% PHVS · CYTK · LYEL · MAZE · RLAY · XENE · ALEC PHVS · CYTK · EIKN · LYEL · RLAY · XENE · ALEC · MAZE
2026-Q2 ★ 62% 83% 71% PHVS · CYTK · EIKN · LYEL · RLAY · XENE · ALEC · MAZE PHVS · CYTK · EIKN · RLAY · XENE · CRNX

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Foresite Capital Management IV, LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, Foresite Capital Management IV, LLC reported 6 equity positions worth $290.15M in aggregate; its largest disclosed positions were PHVS ($165.24M), CYTK ($60.88M), EIKN ($25.37M).

How large is Foresite Capital Management IV, LLC's portfolio?

Foresite Capital Management IV, LLC reported $290.15M of long equity holdings across 6 positions as of 2026-Q2. Top-10 holdings account for 100.0% of reported value.

What is Foresite Capital Management IV, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/foresite-capital-management-iv/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →